A randomized, 32 week double-blind, parallel-group, multicenter study to compare the efficacy and safety of initiating treatment with combination (aliskiren/amlodipine) therapy in comparison with the ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-004242-83

A randomized, 32 week double-blind, parallel-group, multicenter study to compare the efficacy and safety of initiating treatment with combination (aliskiren/amlodipine) therapy in comparison with the sequential add-on treatment strategies in patients with essential hypertension

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

1. To evaluate if initiating treatment with a combination is superior compared to the average of the sequential add-on treatment strategies in reduction of the overall mean over weeks 8, 16, and 24 in the change from baseline in msSBP 2. To evaluate under proof of principle that starting treatment with a combination regimen is superior compared to the average of the sequential add-on treatment strategies in final achieved reduction from baseline to week 24 in msSBP


Critère d'inclusion

  • Hypertension